Dtsch Med Wochenschr 2008; 133(24): 1313-1316
DOI: 10.1055/s-2008-1077233
Aktuelle Diagnostik & Therapie | Review article
Kardiologie, Hypertensiologie, Urologie
© Georg Thieme Verlag KG Stuttgart · New York

Erektile Dysfunktion als kardiovaskulärer Risikomarker

Bedeutung des Renin-Angiotensin-SystemsErectile dysfunction as cardiovascular risk marker Role of the renin-angiotensin systemM. Böhm1 , M. T. Kratz1 , N. Schlimmer1 , M. Baumhäkel1
  • 1Klinik für Innere Medizin III, Kardiologie, Angiologie und Internistische Intensivmedizin, Universitätsklinikum des Saarlandes, Homburg/Saar (M. Böhm und M.T. Kratz sind beide Erstautoren dieser Publikation)
Further Information

Publication History

eingereicht: 21.2.2008

akzeptiert: 6.5.2008

Publication Date:
13 May 2008 (online)

Literatur

  • 1 Baumhäkel M, Böhm M. Erectile dysfunction correlates with left ventricular function and precedes cardiovascular events in cardiovascular high-risk patients.  Int J Clin Pract. 2007;  61 361-366
  • 2 Becker A J, Uckert S, Stief C G, Truss M C, Machtens S, Scheller F, Knapp W H, Hartmann U, Jonas U. Possible role of bradykinin and angiotensin II in the regulation of penile erection and detumescence.  Urology. 2001;  57 193-198
  • 3 Böhm M. Angiotensin receptor blockers versus angiotensin-converting enzyme inhibitors: Where do we stand now?.  Am J Cardiol. 2007;  100 (suppl) 38J-44J
  • 4 Böhm M, Baumhäkel M, Probstfield J L, Schmieder R, Yusuf S, Zhao F, Koon T. on Behalf of the ONTARGET/TRANSCEND ED-Investigators . Sexual function, satisfaction and association of erectile dysfunction with cardiovascular disease and risk factors in cardiovascular high-risk patients: Substudy of the ONgoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNT Study in ACE-Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND).  Am Heart J. 2007;  154 94-101
  • 5 Braun M, Wassmer G, Klotz T. et al . Epidemiology of erectile dysfunction: results of the „Cologne Male Survey”.  Int J Impot Res. 2000;  12 305-311
  • 6 Düsing R. Effect of the angiotensin II antagonist valsartan on sexual function in hypertensive men.  Blood Press (Suppl). 2003;  2 29-34
  • 7 Fogari R, Zoppi A, Corradi L, Mugellini A, Poletti L, Lusardi P. Sexual function in hypertensive males treated with lisinopril or atenolol: a cross-over study.  Am J Hypertens. 1998;  11 (10) 1244-1247
  • 8 Fogari R, Zoppi A, Poletti L. et al . Sexual activity in hypertensive men treated with valsartan or carvedilol: a crossover study.  Am J Hypertens. 2001;  14 27-31
  • 9 Friedrich E B, Teo K K, Böhm M. ACE inhibition in secondary prevention: are the results controversial?.  Clin Res Cardiol. 2006;  95 (2) 61-67
  • 10 Grimm Jr R H, Grandits G A, Prineas R J. et al . Long-term effects on sexual function of five antihypertensive drugs and nutritional hygienic treatment in hypertensive men and women. Treatment of Mild Hypertension Study (TOMHS).  Hypertension. 1997;  29 8-14
  • 11 Kifor I, Williams G H, Vickers M A, Sullivan M P Jodbert P, Dluhy R G. Tissue angiotensin II as a modulator of erectile function. I. Angiotensin peptide content, secretion and effects in the corpus cavernosum.  J Urol. 1997;  157 1920-1925
  • 12 Modebe O. Erectile failure among medical clinic patients.  Afr J Med Med Sci. 1990;  19 (4) 259-264
  • 13 Montorsi P, Ravagnani P, Galli S. et al . Association between erectile dysfunction and coronary artery disease. Role of coronary clinical presentation and extent of coronary vessels involvement: the COBRA trial.  Eur Heart J. 2006;  27 2632-2639
  • 14 Muller S C, el-Damanhoury H, Ruth J, Lue T F. Hypertension and impotence.  Eur Urol. 1991;  19 (1) 29-34
  • 15 Nickenig G, Bäumer A T, Temur Y, Kebben D, Stäblein A, Jockenhövel F, Böhm M. Statin-sensitive dysregulated AT1-receptor function and density in hyercholesterolemic men.  Circulation. 1999;  100 2131-2134
  • 16 Silvestri A, Galetta P, Cerquetani E. et al . Report of erectile dysfunction after therapy with beta-blockers is related to patient knowledge of side effects and is reversed by placebo.  Eur Heart J. 2003;  24 1928-1932
  • 17 The ONTARGET/TRANSCEND Investigators Hamilton, Ontario, Canada . Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: The Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials.  Am Heart J. 2004;  148 52-61
  • 18 Warnholtz A, Nickenig G, Schulz E, Macharzina R, Brasen J H, Skatchov M, Heitzer T, Stasch J P, Griendling K K, Harrison D G, Böhm M, Meinertz T, Münzel T. Increased NADH-oxidase-mediated superoxide production in the early stages of atherosclerosis: evidence for involvement of the renin-angiotensin system.  Circulation. 1999;  99 (15) 2027-2033
  • 19 Yavuzgil O, Altay B, Zoghi M, Gurgun C, Kayikcioglu M, Kultursay H. Endothelial function in patients with vasulogenic erectile dysfunction.  Int J Cardiol. 2005;  103 (1) 19-26

Prof. Dr. Michael Böhm

Klinik für Innere Medizin III, Kardiologie, Angiologie und Internistische Intensivmedizin, Universitätsklinikum des Saarlandes

Kirrberger Straße

66421 Homburg/Saar

Phone: 06841/16-23372

Fax: 06841/16-23369

Email: boehm@uks.eu

    >